Company intelligence / Profile preview

Conatus Pharmaceuticals Inc.

San Diego, California, United Statesconatuspharma.com ↗

Ownership: Private
Employees: ~26
Development stage: Other

Overview

Conatus Pharmaceuticals was focused on developing novel medicines to treat liver disease. Their lead compound, emricasan, was being developed for liver cirrhosis but was discontinued. Other compounds in their pipeline (IDN-1529, RS-130830, IDN-1965, IDN-6734) were also discontinued or remained in preclinical stages.

Therapeutic areas: GastroenterologyCardiovascularInfectious DiseasesRheumatology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

4 assets

emricasan

3 more assets in the full pipeline.

Partnerships

Novartis (exclusive option, collaboration and license agreement for the global development and commercialization of emricasan)

Beyond the preview

Go deeper on Conatus Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conatus Pharmaceuticals Inc..